Advertisement

Targeting DNA Repair

  • Giuseppe CuriglianoEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 249)

Abstract

Genomic instability is a characteristic of most human cancers and plays critical roles in both cancer development and progression. There are various forms of genomic instability arising from many different pathways, such as DNA damage from endogenous and exogenous sources, centrosome amplification, telomere damage, and epigenetic modifications. DNA-repair pathways can enable tumor cells to survive DNA damage. The failure to respond to DNA damage is a characteristic associated with genomic instability. Understanding of genomic instability in cancer is still very limited, but the further understanding of the molecular mechanisms through which the DNA damage response (DDR) operates, in combination with the elucidation of the genetic interactions between DDR pathways and other cell pathways, will provide therapeutic opportunities for the personalized medicine of cancer.

Keywords

Cancer DNA damage Instability Resistance 

References

  1. Artandi SE, DePinho RA (2010) Telomeres and telomerase in cancer. Carcinogenesis 31:9–18PubMedGoogle Scholar
  2. Aubert G, Lansdorp PM (2008) Telomeres and aging. Physiol Rev 88:557–579PubMedGoogle Scholar
  3. Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251PubMedPubMedCentralGoogle Scholar
  4. Bartkova J, Hořejší Z, Koed K et al (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864–870PubMedGoogle Scholar
  5. Bartkova J, Rezaei N, Liontos M et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444:633–637PubMedGoogle Scholar
  6. Bedikian AY, Papadopoulos NE, Kim KB et al (2009) A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 27:756–763PubMedGoogle Scholar
  7. Bell O, Tiwari VK, Thoma NH, Schubeler D (2011) Determinants and dynamics of genome accessibility. Nat Rev Genet 12:554–564PubMedGoogle Scholar
  8. Blackburn EH (2000) Telomeres and telomerase. J Med 49:59–65Google Scholar
  9. Bouwman P, Aly A, Escandell JM et al (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17:688–695PubMedPubMedCentralGoogle Scholar
  10. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917PubMedGoogle Scholar
  11. Bundred N, Gardovskis J, Jaskiewicz J et al (2013) Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicenter trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 31:949–958PubMedGoogle Scholar
  12. Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:295–304PubMedGoogle Scholar
  13. Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40:179–204PubMedPubMedCentralGoogle Scholar
  14. David SS, O’Shea VL, Kundu S (2007) Base-excision repair of oxidative DNA damage. Nature 447:941–950PubMedPubMedCentralGoogle Scholar
  15. de Lange T (2010) How shelterin solves the telomere end-protection problem. Cold Spring Harb Symp Quant Biol 75:167–177PubMedGoogle Scholar
  16. Dean E, Middleton MR, Pwint T et al (2012) Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 106:468–474PubMedPubMedCentralGoogle Scholar
  17. Del Conte G, Sessa C, von Moos R et al (2014) Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 111:651–659PubMedPubMedCentralGoogle Scholar
  18. Dent RA, Lindeman GJ, Clemons M et al (2013) Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 15:R88PubMedPubMedCentralGoogle Scholar
  19. Di Micco R, Fumagalli M, Cicalese A et al (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature 444:638–642PubMedGoogle Scholar
  20. Doxsey S (2001) Re-evaluating centrosome function. Nat Rev Mol Cell Biol 2:688–698PubMedGoogle Scholar
  21. Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283:593–596PubMedGoogle Scholar
  22. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937–948PubMedGoogle Scholar
  23. Fang X, Zhang R (2011) Aneuploidy and tumourigenesis. Semin Cell Dev Biol 22:595–601PubMedPubMedCentralGoogle Scholar
  24. Ferguson LR, Chen H, Collins AR et al (2015) Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol 35:S5–S24PubMedPubMedCentralGoogle Scholar
  25. Fishel R, Lescoe MK, Rao MRS, Copeland NG (1993) The human mutator gene homolog MSH2 and its association with hereditary non-polyposis colon cancer. Cell 75:1027–1038PubMedGoogle Scholar
  26. Fong PC, Yap TA, Boss DS et al (2009) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–2519Google Scholar
  27. Frizzell KM, Kraus WL (2009) PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2? Breast Cancer Res 11:111PubMedPubMedCentralGoogle Scholar
  28. Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852–861Google Scholar
  29. Gergely F, Basto R (2008) Multiple centrosomes: together they stand, divided they fall. Genes Dev 22:2291–2296PubMedPubMedCentralGoogle Scholar
  30. Glover DM, Leibowitz MH, McLean DA et al (1995) Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 891:95–105Google Scholar
  31. Gorgoulis VG, Vassiliou LVF, Karakaidos P et al (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907–913PubMedGoogle Scholar
  32. Greider CW (1991) Telomeres. Curr Opin Cell Biol 3:444–451PubMedGoogle Scholar
  33. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319:1352–1355PubMedGoogle Scholar
  34. Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb. Mutat Res 256:271–282PubMedGoogle Scholar
  35. Harley CB, Sherwood SW (1997) Telomerase, checkpoints and cancer. Cancer Surv 29:263–284PubMedGoogle Scholar
  36. Helleday T, Petermann E, Lundin C et al (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8:193–204PubMedGoogle Scholar
  37. Hitchins MP (2010) Inheritance of epigenetic aberrations (constitutional epimutations) in cancer susceptibility. Adv Genet 70:201–243PubMedGoogle Scholar
  38. Hockemeyer D, Sfeir AJ, Shay JW et al (2005) POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. EMBO J 24:2667–2678PubMedPubMedCentralGoogle Scholar
  39. Hoeijmakers JH (2009) DNA damage, aging, and cancer. N Engl J Med 361:1475–1485PubMedGoogle Scholar
  40. Isakoff SJ, Overmoyer B, Tung NM et al (2010) A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. ASCO annual meeting abstracts. J Clin Oncol 28(15_suppl):1019Google Scholar
  41. Jirincy J (2006) The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7:335–346Google Scholar
  42. Karlseder J, Hoke K, Mirzoeva OK et al (2004) The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. PLoS Biol 2:E240PubMedPubMedCentralGoogle Scholar
  43. Khodjakov A (2002) De novo formation of centrosomes in vertebrate cells arrested during S phase. J Cell Biol 158:1171–1181PubMedPubMedCentralGoogle Scholar
  44. Ko MA, Rosario CO, Hudson JW et al (2005) Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 37:883–888PubMedGoogle Scholar
  45. Konishi A, de Lange T (2008) Cell cycle control of telomere protection and NHEJ revealed by a ts mutation in the DNA-binding domain of TRF2. Genes Dev 22:1221–1230PubMedPubMedCentralGoogle Scholar
  46. Kummar S, Kinders R, Gutierrez ME et al (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705–2711PubMedPubMedCentralGoogle Scholar
  47. Kwon M, Godinho SA, Chandhok NS et al (2008) Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 22:2189–2203PubMedPubMedCentralGoogle Scholar
  48. Leach FS, Nicolaides NC, Papadopoulos N, Liu B (1993) Mutations of a mutS homolog in hereditary non-polyposis colorectal cancer. Cell 75:1215–1225PubMedGoogle Scholar
  49. Lee JH, Jeong SY, Kim MJ et al (2015) MicroRNA-22 suppresses DNA repair and promotes genomic instability through targeting of MDC1. Cancer Res 75:1298PubMedGoogle Scholar
  50. Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386:623–627PubMedGoogle Scholar
  51. Levy MZ, Allsopp RC, Futcher AB et al (1992) Telomere end-replication problem and cell aging. J Mol Biol 225:951–960PubMedGoogle Scholar
  52. Levy-Lahad E (2010) Fanconi anemia and breast cancer susceptibility meet again. Nat Genet 42:368–369PubMedGoogle Scholar
  53. Lieber MR (2010) NHEJ and its backup pathways in chromosomal translocations. Nat Struct Mol Biol 17:393–395PubMedPubMedCentralGoogle Scholar
  54. Lindahl T, Barnes DE (2000) Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol 65:127–133PubMedGoogle Scholar
  55. Liu JF, Tolaney SM, Birrer M et al (2013) A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49:2972–2978PubMedPubMedCentralGoogle Scholar
  56. Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075–3079PubMedGoogle Scholar
  57. Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287PubMedGoogle Scholar
  58. Mailand N, Bekker-Jensen S, Faustrup H et al (2007) RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131:887–900PubMedGoogle Scholar
  59. Marthien V, Piel M, Basto RJ (2012) Never tear us apart – the importance of centrosome clustering. Cell Sci 125:3281–3292Google Scholar
  60. Maxwell CA, Keats JJ, Belch AR et al (2005) Receptor forhyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res 56:850–860Google Scholar
  61. McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109–8115PubMedGoogle Scholar
  62. Miquel C, Jacob S, Grandjouan S et al (2007) Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26:5919–5926PubMedGoogle Scholar
  63. Moynahan ME, Jasin M (2010) Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 11:196–207PubMedPubMedCentralGoogle Scholar
  64. Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability – an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:220–228PubMedGoogle Scholar
  65. Nigg EA (2002) Centrosome aberrations: cause or consequence of cancer progression. Nat Rev Cancer 2:815–825PubMedGoogle Scholar
  66. Nigg EA, Stearns T (2011) The centrosome cycle: centriole biogenesis, duplication and inherent asymmetries. Nat Cell Biol 13:1154–1160PubMedPubMedCentralGoogle Scholar
  67. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28PubMedGoogle Scholar
  68. O’Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214PubMedGoogle Scholar
  69. Ogden A, Rida PC, Aneja R (2012) Let’s huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy. Cell Death Differ 19:1255–1267PubMedPubMedCentralGoogle Scholar
  70. Papoutsis AJ, Borg JL, Selmin OI, Romagnolo DF (2012) BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. J Nutr Biochem 23:1324–1332PubMedGoogle Scholar
  71. Penning TD, Zhu GD, Gandhi VB et al (2009) Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-Yl]-1h-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52:514–523PubMedGoogle Scholar
  72. Plummer R, Jones C, Middleton M et al (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917–7923PubMedPubMedCentralGoogle Scholar
  73. Plummer R, Lorigan P, Steven N et al (2013) A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 71:1191–1199PubMedGoogle Scholar
  74. Plummer R, Stephens P, Aissat-Daudigny L et al (2014) Phase 1 dose escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol 74:257–265PubMedPubMedCentralGoogle Scholar
  75. Rajagopalan H, Lengauer C (2004) Aneuploidy and cancer. Nature 432:338–341PubMedGoogle Scholar
  76. Rajan A, Carter CA, Kelly RJ et al (2012) A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 18:2344–2351PubMedGoogle Scholar
  77. Rouleau M, Patel A, Hendzel MJ et al (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293–301PubMedPubMedCentralGoogle Scholar
  78. Samol J, Ranson M, Scott E et al (2012) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs 30:1493–1500PubMedGoogle Scholar
  79. Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADPribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517–528PubMedGoogle Scholar
  80. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27–36PubMedGoogle Scholar
  81. Sproul D, Gilbert N, Bickmore WA (2005) The role of chromatin structure in regulating the expression of clustered genes. Nat Rev Genet 6:775–781PubMedGoogle Scholar
  82. Swann PF, Waters TR, Moulton DC (1996) Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273:1109–1111PubMedGoogle Scholar
  83. Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244Google Scholar
  84. Vilar E, Bartnik CM, Stenzel SL et al (2011) MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71:2632–2642PubMedPubMedCentralGoogle Scholar
  85. Warmerdam DO, Kanaar R (2010) Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat Res 704:2–11PubMedGoogle Scholar
  86. Yamamoto N, Nokihara H, Yamada Y et al (2012) A phase I, dosefinding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci 103:504–509PubMedGoogle Scholar
  87. Zhai L, Li S, Li X et al (2015) The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity. Pathol Res Pract 211:130–137PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Early Drug Development for Innovative Therapy DivisionEuropean Institute of OncologyMilanItaly

Personalised recommendations